Literature DB >> 25443235

Antiarrhythmic drug therapy for atrial fibrillation.

Muhammad Rizwan Sardar1, Wajeeha Saeed2, Peter R Kowey3.   

Abstract

Atrial fibrillation (AF) is the most frequently encountered arrhythmia. Prevalence increases with advancing age and so as its associated comorbidities, like heart failure. Choice of pharmacologic therapy depends on whether the goal of treatment is maintaining sinus rhythm or tolerating AF with adequate control of ventricular rates. Antiarrhythmic therapy and conversion of AF into sinus rhythm comes with the side effect profile, and we should select best antiarrhythmic therapy, individualized to the patient. New antiarrhythmic drugs are being tested in clinical trials. Drugs that target remodeling and inflammation are being tested for their use as prevention of AF or as upstream therapy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiarrhythmic; Atrial fibrillation; Cardioversion; Pharmacologic therapy; Prevention; Rate control; Rhythm control; Upstream therapy

Mesh:

Substances:

Year:  2014        PMID: 25443235     DOI: 10.1016/j.ccl.2014.07.012

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  1 in total

1.  A snapshot of genetic and epigenetic basis of arrhythmia and heart failure.

Authors:  Junjie Xiao; Joost P G Sluijter; Saumya Das; Yiqing Yang; Zhongming Shen
Journal:  Front Genet       Date:  2015-03-03       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.